Mainstay Medical International, the medical device company that brought ReActiv8 to the market, has announced the resignation of Hugh Kavanagh as chief financial officer. 

“On behalf of Mainstay’s Board, management team and staff, I would like to thank Hugh for his substantial contribution to the growth of the company," CEO Jason Hannon said. "The company plans to announce the appointment of a new CFO in the coming months. We are pleased that Hugh will continue to support the company through this transition.”

Kavanagh has been Mainstay’s CFO since 2013. In 2014, he led the company through its IPO on Euronext Paris and the ESM of the Irish Stock Exchange, as well as its subsequent debt and equity fundraisings. Kavanagh also led the company’s financial aspects during the development of ReActiv8 as well as its commercialization in Europe. 

His departure is scheduled for Aug. 21.